DrugPatentWatch Database Preview
VECTIBIX Drug Profile
Summary for Tradename: VECTIBIX
| Patents: | 275 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for VECTIBIX |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VECTIBIX |
Recent Clinical Trials for VECTIBIX
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Emory University | Phase 2 |
| Tesaro, Inc. | Phase 2 |
| Academic and Community Cancer Research United | Phase 2 |
Recent Litigation for VECTIBIX
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| PIECZENIK v. BAYER CORPORATION | 2010-05-04 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Forty Seven, Inc. | 2018-01-08 |
| Forty Seven, Inc. | 2016-08-08 |
| Forty Seven, Inc. | 2016-08-05 |
Pharmacology for VECTIBIX
| Ingredient-type | Antibodies, Monoclonal |
| Mechanism of Action | HER1 Antagonists |
Company Disclosures: US Patents for VECTIBIX
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | Abgenix, Inc. (Fremont, CA) | 2039-02-26 | RX | company | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | Amgen Fremont Inc. (Fremont, CA) | 2017-05-05 | RX | company | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 002 | 2006-09-27 | Start Trial | Abgenix, Inc. (Fremont, CA) | 2039-02-26 | RX | company | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 002 | 2006-09-27 | Start Trial | Amgen Fremont Inc. (Fremont, CA) | 2017-05-05 | RX | company | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 003 | 2006-09-27 | Start Trial | Abgenix, Inc. (Fremont, CA) | 2039-02-26 | RX | company | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 003 | 2006-09-27 | Start Trial | Amgen Fremont Inc. (Fremont, CA) | 2017-05-05 | RX | company | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for VECTIBIX
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | VentiRx Pharmaceuticals, Inc. (Seattle, WA) | 2030-04-21 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | University of Georgia Research Foundation, Inc. (Athens, GA) | 2039-02-26 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | Roche Molecular Systems, Inc. (Pleasanton, CA) | 2031-01-11 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | AMGEN, INC (Thousand Oaks, CA) | 2027-03-13 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | MEDIMMUNE, LLC (Gaithersburg, MD) | 2031-11-23 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | Celcuity LLC (Minneapolis, MN) | 2032-06-12 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for VECTIBIX
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Philippines | 12015502088 | Start Trial |
| Mexico | 2009003982 | Start Trial |
| Canada | 2936785 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2015117952 | Start Trial |
| Japan | 2015157832 | Start Trial |
| Australia | 2016365829 | Start Trial |
| Japan | 2009532673 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for VECTIBIX
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| PA2008001,C0979246 | Lithuania | Start Trial | PRODUCT NAME: PANITUMUMABUM; REGISTRATION NO/DATE: EU/1/07/423/001, EU/1/07/423/002, EU/1/07/423/003 20071203 |
| PA2008001 | Lithuania | Start Trial | PRODUCT NAME: PANITUMUMABUM; REGISTRATION NO/DATE: ANUM>EU/1/07/423/001-003 20071203 |
| C00979246/01 | Switzerland | Start Trial | PRODUCT NAME: PANITUMUMABUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 57872 14.10.2008 |
| SPC005/2008 | Ireland | Start Trial | SPC005/2008: 20081105, EXPIRES: 20221202 |
| 91411 | Luxembourg | Start Trial | 91411, EXPIRES: 20221203 |
| SPC/GB08/009 | United Kingdom | Start Trial | PRODUCT NAME: PANITUMUMAB; REGISTERED: UK EU/1/07/423/001 20071205; UK EU/1/07/423/002 20071205; UK EU/1/07/423/003 20071205 |
| 344 | Finland | Start Trial | |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
